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Exposure of infants to antiretroviral drugs for pre-
vention of mother-to-child transmission can
induce resistance to nucleoside/nucleotide reverse
transcriptase inhibitors (NRTIs). Data from nine
national surveys of pretreatment drug resistance in
children newly diagnosed with HIV show high
levels of resistance to NRTIs included in first-line
antiretroviral treatment (ART) regimens (dual aba-
cavir-lamivudine/emtricitabine resistance). Addi-
tional research is needed to determine the impact
of NRTI resistance on treatment response and
optimize infant ART.
Exposure of infants to antiretroviral drugs for prevention
of mother-to-child transmission (PMTCT) can induce
resistance to nucleoside/nucleotide reverse transcriptase
inhibitors (NRTIs) [1–5].
We assessed the prevalence of NRTI resistance in ART-
naı̈ve children 18 months or less of age who were newly
diagnosed with HIV through early infant diagnosis
programs. Data were obtained from nine nationally
representative surveys in sub-Saharan Africa, conducted
between 2011 and 2016 in Eswatini (2011), Uganda
(2011), Mozambique (2012), Togo (2012), Zimbabwe
(2012), Cameroon (2014), South Africa (2014), Nigeria
(2016), and Malawi (2016).
Drug resistance was predicted using the Stanford HIVdb
algorithm Version 8.3 [6]. Sequences classified as having
low-level, intermediate-level or high-level resistance
were designated ‘resistant’. Prevalence estimates were
calculated for each country using Stata 14 (StataCorp,
College Station, Texas, USA) as per the survey analysis
plan [7]. Differences between groups were assessed on
unweighted data by logistic regression. Nonresearch
determination approval for routine surveillance studies
was obtained from the individual countries’ national
research ethics committees.
Data on HIV drug resistance and antiretroviral prophy-
laxis were available for 2684 and 2282 (85%) infants (all
surveys except South Africa), respectively (Table 1). Of
the infants, 1229 (53.9%) were exposed to maternal
prophylaxis.
The prevalence of NRTI resistance in the nine surveys
ranged from 2.0% (95% CI: 0.1–4.0) to 25.8% (95% CI:
17.5–36.4) and was significantly higher in surveys
conducted after in-country adoption of the WHO’s
policy for maternal lifelong ART [23.4 (95% CI: 19.4–
27.9) vs. 9.9 (95% CI: 8.6–11.1, P< 0.0001]. The
prevalence of NRTI resistance was also higher among
infants exposed to maternal prophylaxis (with or without
infant prophylaxis) compared with those exposed to only
infant prophylaxis or with unknown exposure history
(Table 1).
NRTI resistance was mainly driven by abacavir (ABC)
and emtricitabine/lamivudine (XTC) resistance. The
prevalence of dual ABC/XTC resistance ranged from 2%
in Eswatini (2011) to 28.1% in Nigeria (2016) (Table 1).
Overall, the prevalence of resistance to zidovudine (ZDV)
and tenofovir (TDF) was less than 10% across all surveys
except in Togo where ZDV resistance was 11.6%, and in
Nigeria where ZDV and TDF resistance were 15% and
11.3%, in infants exposed to maternal prophylaxis,
respectively.
We made several key observations in this study. First,
children exposed to maternal prophylaxis had higher
levels of NRTI resistance compared with infants not
exposed to maternal prophylaxis. This is consistent with
previous studies that showed selection of drug-resistant
HIV in children exposed to sub-therapeutic concentra-
tions of maternal drugs ingested during breast-feeding
[1,5]. Similar to findings from recent studies, we observed
higher levels of NRTI resistance in surveys conducted
after adoption of WHO recommendations for maternal
lifelong ART; this suggests that the prevalence of NRTI
resistance could increase further over time as the WHO
policy is more widely implemented [3,4].
Second, although WHO recommends ritonavir-boosted
protease-inhibitor (PI/r)-based first-line pediatric regi-
mens in children greater than 4 weeks of age who weigh
less than 20 kg, this recommendation has not been widely
implemented in many sub-Saharan African countries
because of limited availability and high cost of pediatric-
friendly formulations. Consequently, NNRTI-based
regimens are still widely used [8]. The increasing
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prevalence of NRTI resistance, combined with still
substantial use of NNRTI-based ART (for which
resistance exceeds 50%) in infants [9,10], suggests that
most young children may be treated ineffectively and risks
poor treatment outcomes. These findings emphasize the
urgent need to accelerate access to child-friendly PI/r-
based regimens.
Third, although PI/r regimens have been shown to
remain effective in those who have resistance to two co-
administered NRTIs [11], most studies have been
conducted in adults receiving regimens that include
TDF/XTC or ZDV/XTC. It is not clear whether these
findings can be extrapolated to children receiving
regimens with ABC/XTC. The efficacy of PI/r-based
regimens in the setting of NRTI resistance is partially
attributed to an antagonistic effect of the M184 V
mutation; this mutation causes hyper-susceptibility of
HIV to ZDV and TDF, but not to ABC [12]. Additional
studies are needed to assess the efficacy of PI/r-based
regimens in children with resistance to ABC.
Although ZDV and TDF are potential alternatives to
ABC, we find that resistance to these drugs may also be
high in some countries. This suggests the need to
accelerate research and access to newer NRTIs and
nucleoside-sparing ART combinations particularly for
this population.
Fourth, our findings have direct implications for pediatric
regimens recommended in the 2019 WHO guidelines
(i.e. raltegravir in infants <4 weeks of age and
dolutegravir in children weighing >20 kg) [13]. As
raltegravir has a low genetic barrier for resistance [14], its
use in neonates with NRTI resistance may lead to
emergence of resistance, potentially compromising future
use of dolutegravir [15,16]. There is limited evidence to
support the use of dolutegravir in infants with NRTI
resistance. Therefore, caution is needed when consider-
ing use of dolutegravir with ABC/XTC in young
children in countries with a high prevalence of ABC/
XTC resistance.
Given the limited number of ART regimens available to
children living with HIV, careful attention is needed to
avoid inducing NRTI resistance early in life. The WHO
recommendation for use of triple-drug neonatal prophy-
laxis (or presumptive treatment) should be considered in
low-income and middle-income countries [17].
This study has several limitations. First, we may have
overestimated the prevalence of ABC resistance by using
the Stanford HIVdb algorithm; this algorithm classifies
the M184V mutation as causing low-level ABC resistance
(https://hivdb.stanford.edu, accessed 21 November,
2019). However, findings from the CNA3003 study
[18], as well as the REGA and French ANRS drug
resistance interpretation algorithms, suggest a minimal
impact of this mutation on ABC resistance (https://
hivdb.stanford.edu, accessed 21 November, 2019). When
we excluded M184V as a cause of ABC resistance, the
prevalence dropped from 19.8% to 12.7% in Nigeria and
from 20.6% to 12.6% in Malawi. Second, our findings
were from regions where most women on ART were
receiving NNRTI-based therapy. Additional studies are
needed to estimate the prevalence of NRTI resistance in
infants, whose mothers were taking dolutegravir-based
regimens. Dolutegravir is also transferred through breast-
milk at concentrations that are unlikely to suppress HIV
replication fully [19], and may potentially select for both
dolutegravir and NRTI resistance.
In conclusion, the increasing prevalence of ABC and
XTC resistance in infants who are infected with HIV
despite antiretroviral prophylaxis merits attention. Fur-
ther studies are needed to understand the impact NRTI
on pediatric regimens.
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Nonmelanoma skin cancer and melanoma in HIV-
1-infected patients
Alessandra Latinia, Lavinia Aleia, Francesca Magrib,
Laura Eibenschutzc, Carlo Cotad, Maria Gabriella
Dona’a, Norma Camelia, Antonio Cristaudoa and
Mauro Zaccarellie
In the cART era, the incidence of AIDS-defining
cancers decreased, whereas a persistence of non-
AIDS-defining cancers has been observed. In par-
ticular, concerning the risk of melanoma and non-
melanoma skin cancers in HIV patients, conflicting
data are available. In this study, our aim was to
assess the occurrence of cutaneous malignancies in
97 HIV-positive individuals visited in our Institute,
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